Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

IMP1 KH1 and KH2 domains create a structural platform with unique RNA recognition and re-modelling properties.

Dagil R, Ball NJ, Ogrodowicz RW, Hobor F, Purkiss AG, Kelly G, Martin SR, Taylor IA, Ramos A.

Nucleic Acids Res. 2019 May 7;47(8):4334-4348. doi: 10.1093/nar/gkz136.

2.

Structure of DNA-CMG-Pol epsilon elucidates the roles of the non-catalytic polymerase modules in the eukaryotic replisome.

Goswami P, Abid Ali F, Douglas ME, Locke J, Purkiss A, Janska A, Eickhoff P, Early A, Nans A, Cheung AMC, Diffley JFX, Costa A.

Nat Commun. 2018 Nov 29;9(1):5061. doi: 10.1038/s41467-018-07417-1.

3.

Erratum: Structural Basis of Eco1-Mediated Cohesin Acetylation.

Chao WC, Wade BO, Bouchoux C, Jones AW, Purkiss AG, Federico S, O'Reilly N, Snijders AP, Uhlmann F, Singleton MR.

Sci Rep. 2017 Apr 11;7:46382. doi: 10.1038/srep46382. No abstract available.

4.

Structural Basis of Eco1-Mediated Cohesin Acetylation.

Chao WC, Wade BO, Bouchoux C, Jones AW, Purkiss AG, Federico S, O'Reilly N, Snijders AP, Uhlmann F, Singleton MR.

Sci Rep. 2017 Mar 14;7:44313. doi: 10.1038/srep44313. Erratum in: Sci Rep. 2017 Apr 11;7:46382.

5.

Structure of the cohesin loader Scc2.

Chao WC, Murayama Y, Muñoz S, Jones AW, Wade BO, Purkiss AG, Hu XW, Borg A, Snijders AP, Uhlmann F, Singleton MR.

Nat Commun. 2017 Jan 6;8:13952. doi: 10.1038/ncomms13952.

6.

aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization.

Soriano EV, Ivanova ME, Fletcher G, Riou P, Knowles PP, Barnouin K, Purkiss A, Kostelecky B, Saiu P, Linch M, Elbediwy A, Kjær S, O'Reilly N, Snijders AP, Parker PJ, Thompson BJ, McDonald NQ.

Dev Cell. 2016 Aug 22;38(4):384-98. doi: 10.1016/j.devcel.2016.07.018.

7.

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.

Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJR, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, Jones SD, Jordan AM, Lyons AJ, Nikki March H, McDonald NQ, Maguire LA, Mould DP, Purkiss AG, Small HF, Stowell AIJ, Thomson GJ, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Eur J Med Chem. 2016 Apr 13;112:20-32. doi: 10.1016/j.ejmech.2016.01.039. Epub 2016 Jan 29.

8.

Structures of the human Pals1 PDZ domain with and without ligand suggest gated access of Crb to the PDZ peptide-binding groove.

Ivanova ME, Fletcher GC, O'Reilly N, Purkiss AG, Thompson BJ, McDonald NQ.

Acta Crystallogr D Biol Crystallogr. 2015 Mar;71(Pt 3):555-64. doi: 10.1107/S139900471402776X. Epub 2015 Feb 26.

9.

RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association.

Goodman KM, Kjær S, Beuron F, Knowles PP, Nawrotek A, Burns EM, Purkiss AG, George R, Santoro M, Morris EP, McDonald NQ.

Cell Rep. 2014 Sep 25;8(6):1894-1904. doi: 10.1016/j.celrep.2014.08.040. Epub 2014 Sep 18.

10.

Structure of the human FANCL RING-Ube2T complex reveals determinants of cognate E3-E2 selection.

Hodson C, Purkiss A, Miles JA, Walden H.

Structure. 2014 Feb 4;22(2):337-44. doi: 10.1016/j.str.2013.12.004. Epub 2014 Jan 2.

11.

A cancer-associated mutation in atypical protein kinase Cι occurs in a substrate-specific recruitment motif.

Linch M, Sanz-Garcia M, Soriano E, Zhang Y, Riou P, Rosse C, Cameron A, Knowles P, Purkiss A, Kjaer S, McDonald NQ, Parker PJ.

Sci Signal. 2013 Sep 17;6(293):ra82. doi: 10.1126/scisignal.2004068.

PMID:
24045153
12.

A molecular explanation for the recessive nature of parkin-linked Parkinson's disease.

Spratt DE, Martinez-Torres RJ, Noh YJ, Mercier P, Manczyk N, Barber KR, Aguirre JD, Burchell L, Purkiss A, Walden H, Shaw GS.

Nat Commun. 2013;4:1983. doi: 10.1038/ncomms2983.

13.

14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins.

Riou P, Kjær S, Garg R, Purkiss A, George R, Cain RJ, Bineva G, Reymond N, McColl B, Thompson AJ, O'Reilly N, McDonald NQ, Parker PJ, Ridley AJ.

Cell. 2013 Apr 25;153(3):640-53. doi: 10.1016/j.cell.2013.03.044. Erratum in: Cell. 2013 May 23;153(5):1164.

14.

Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes.

Kjær S, Linch M, Purkiss A, Kostelecky B, Knowles PP, Rosse C, Riou P, Soudy C, Kaye S, Patel B, Soriano E, Murray-Rust J, Barton C, Dillon C, Roffey J, Parker PJ, McDonald NQ.

Biochem J. 2013 Apr 15;451(2):329-42. doi: 10.1042/BJ20121871.

PMID:
23418854
15.

Structural analysis of human FANCL, the E3 ligase in the Fanconi anemia pathway.

Hodson C, Cole AR, Lewis LP, Miles JA, Purkiss A, Walden H.

J Biol Chem. 2011 Sep 16;286(37):32628-37. doi: 10.1074/jbc.M111.244632. Epub 2011 Jul 20.

16.

Explosive expansion of betagamma-crystallin genes in the ancestral vertebrate.

Kappé G, Purkiss AG, van Genesen ST, Slingsby C, Lubsen NH.

J Mol Evol. 2010 Sep;71(3):219-30. doi: 10.1007/s00239-010-9379-2. Epub 2010 Aug 20. Erratum in: J Mol Evol. 2010 Oct;71(4):317-8.

17.

Recognition of an intra-chain tandem 14-3-3 binding site within PKCepsilon.

Kostelecky B, Saurin AT, Purkiss A, Parker PJ, McDonald NQ.

EMBO Rep. 2009 Sep;10(9):983-9. doi: 10.1038/embor.2009.150. Epub 2009 Aug 7.

18.

Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design.

Gooptu B, Miranda E, Nobeli I, Mallya M, Purkiss A, Brown SC, Summers C, Phillips RL, Lomas DA, Barrett TE.

J Mol Biol. 2009 Apr 10;387(4):857-68. doi: 10.1016/j.jmb.2009.01.069. Epub 2009 Feb 14.

19.

Biophysical properties of gammaC-crystallin in human and mouse eye lens: the role of molecular dipoles.

Purkiss AG, Bateman OA, Wyatt K, Wilmarth PA, David LL, Wistow GJ, Slingsby C.

J Mol Biol. 2007 Sep 7;372(1):205-22. Epub 2007 Jun 26.

20.

Urochordate betagamma-crystallin and the evolutionary origin of the vertebrate eye lens.

Shimeld SM, Purkiss AG, Dirks RP, Bateman OA, Slingsby C, Lubsen NH.

Curr Biol. 2005 Sep 20;15(18):1684-9.

21.

Unfolding crystallins: the destabilizing role of a beta-hairpin cysteine in betaB2-crystallin by simulation and experiment.

MacDonald JT, Purkiss AG, Smith MA, Evans P, Goodfellow JM, Slingsby C.

Protein Sci. 2005 May;14(5):1282-92.

22.

Specific interaction between lens MIP/Aquaporin-0 and two members of the gamma-crystallin family.

Fan J, Fariss RN, Purkiss AG, Slingsby C, Sandilands A, Quinlan R, Wistow G, Chepelinsky AB.

Mol Vis. 2005 Jan 25;11:76-87. Erratum in: Mol Vis. 2005 Jan 25;11: 1 p following 87.

23.

Sulfur in human crystallins.

Srikanthan D, Bateman OA, Purkiss AG, Slingsby C.

Exp Eye Res. 2004 Dec;79(6):823-31.

PMID:
15642319
24.

Crystal structure of eta-crystallin: adaptation of a class 1 aldehyde dehydrogenase for a new role in the eye lens.

Bateman OA, Purkiss AG, van Montfort R, Slingsby C, Graham C, Wistow G.

Biochemistry. 2003 Apr 22;42(15):4349-56.

PMID:
12693930
25.

Deamidation in human gamma S-crystallin from cataractous lenses is influenced by surface exposure.

Lapko VN, Purkiss AG, Smith DL, Smith JB.

Biochemistry. 2002 Jul 9;41(27):8638-48.

PMID:
12093281
26.

The X-ray crystal structure of human gamma S-crystallin C-terminal domain.

Purkiss AG, Bateman OA, Goodfellow JM, Lubsen NH, Slingsby C.

J Biol Chem. 2002 Feb 8;277(6):4199-205. Epub 2001 Nov 8.

27.

Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism.

Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW.

Acta Neurol Scand. 1999 Jul;100(1):34-41.

PMID:
10416510
28.

Cortisol is higher in parkinsonism and associated with gait deficit.

Charlett A, Dobbs RJ, Purkiss AG, Wright DJ, Peterson DW, Weller C, Dobbs SM.

Acta Neurol Scand. 1998 Feb;97(2):77-85.

PMID:
9517856
29.

Breadth of base whilst walking: effect of ageing and parkinsonism.

Charlett A, Weller C, Purkiss AG, Dobbs SM, Dobbs RJ.

Age Ageing. 1998 Jan;27(1):49-54.

PMID:
9504366
30.

Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism.

Kirollos C, Charlett A, O'Neill CJ, Kosik R, Mozol K, Purkiss AG, Bowes SG, Nicholson PW, Hunt WB, Weller C, Dobbs SM, Dobbs RJ.

Br J Clin Pharmacol. 1996 Jun;41(6):557-64.

31.

Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism.

Kirollos C, Charlett A, Bowes SG, Purkiss AG, O'Neill CJ, Weller C, Dickins J, Faulkner G, Nicholson PW, Hunt WB, Dobbs RJ, Dobbs SM.

Eur J Clin Pharmacol. 1996;50(1-2):7-18.

PMID:
8739805
32.

Could seborrhoeic dermatitis be implicated in the pathogenesis of parkinsonism?

O'Neill CJ, Richardson MD, Charlett A, McHugh L, Bowes SG, Purkiss AG, Weller C, Dobbs SM, Dobbs RJ.

Acta Neurol Scand. 1994 Apr;89(4):252-7.

PMID:
8042441
33.

Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.

Weller C, O'Neill CJ, Charlett A, Bowes SG, Purkiss A, Nicholson PW, Dobbs RJ, Dobbs SM.

Br J Clin Pharmacol. 1993 Apr;35(4):379-85.

34.

Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers.

Kirollos C, O'Neill CJ, Dobbs RJ, Charlett A, Bowes SG, Weller C, Purkiss AG, Hunt WB, Dobbs SM.

Age Ageing. 1993 Jan;22(1):20-6.

PMID:
8438661
35.

Reduced axial rotation in the spouses of sufferers from clinical idiopathic parkinsonism.

Weller C, Nicholson PW, Dobbs SM, Bowes SG, Purkiss A, Dobbs RJ.

Age Ageing. 1992 May;21(3):189-94.

PMID:
1615781
36.

Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.

Bowes SG, Dobbs RJ, Henley M, Charlett A, O'Neill CJ, Nicholson PW, Purkiss AG, Weller C, Dobbs SM.

Eur J Clin Pharmacol. 1992;43(5):483-9.

PMID:
1483485

Supplemental Content

Loading ...
Support Center